Fintel reports that on May 27, 2025, BTIG downgraded their outlook for Globus Medical (NYSE:GMED) from Buy to Neutral.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.5, a high ...

BTIG analysts have downgraded (NYSE:GMED) from "Buy" to "Neutral" amid fears surrounding the company's Spine business.

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns ...

On Tuesday, May 27, an analyst from BTIG downgraded Globus Medical Inc. (NYSE:GMED) from Buy to Neutral, citing concerns about its Spine business. The analyst did not assign a price target ...

On Tuesday, JMP analysts maintained their Market Perform rating on Globus Medical (NYSE:GMED) shares. The firm’s stance comes after Globus Medical reported its first-quarter results for 2025.

Globus Medical, Inc. has a 1 year low of $54.48 and a 1 year high of $94.93. The firm has a 50 day moving average price of $69.35 and a 200 day moving average price of $78.83.

On Tuesday, BTIG analyst Ryan Zimmerman downgraded Globus Medical shares (NYSE:GMED) from Buy to Neutral, citing concerns following the company’s first-quarter results for 2025. According to ...

On Tuesday, JMP analysts maintained their Market Perform rating on Globus Medical (NYSE:GMED) shares. The firm’s stance comes after Globus Medical reported its first-quarter results for 2025. The ...